Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
Open Access
- 1 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 35 (9), 1679-1697
- https://doi.org/10.1007/s00467-020-04516-4
Abstract
Background Secondary hyperparathyroidism (sHPT), a complication of chronic kidney disease (CKD) characterized by persistently elevated parathyroid hormone (PTH), alterations in calcium-phosphorus homeostasis, and vitamin D metabolism, affects 50% of children receiving dialysis. A significant proportion of these children develop CKD-mineral and bone disorder (CKD-MBD), associated with an increased risk of fractures and vascular calcification. The standard of care for sHPT in children includes vitamin D sterols, calcium supplementation, and phosphate binders. Several agents are approved for sHPT treatment in adults undergoing dialysis, including vitamin D analogs and calcimimetics, with limited information on their safety and efficacy in children. The calcimimetic cinacalcet is approved for use in adults with sHPT on dialysis, but is not approved for pediatric use outside Europe. Methods This review provides dosing, safety, and efficacy information from Amgen-sponsored cinacalcet pediatric trials and data from non-Amgen sponsored clinical studies. Results The Amgen cinacalcet pediatric clinical development program consisted of two Phase 3 randomized studies, one Phase 3 single arm extension study, one open-label Phase 2 study, and two open-label Phase 1 studies. Effects of cinacalcet on PTH varied across studies. Overall, 7.4 to 57.1% of subjects who received cinacalcet in an Amgen clinical trial attained PTH levels within recommended target ranges and 22.2 to 70.6% observed a >= 30% reduction in PTH. In addition, significant reductions in PTH were demonstrated in all non-Amgen-supported studies. Conclusions To help inform the pediatric nephrology community, this manuscript contains the most comprehensive review of cinacalcet usage in pediatric CKD patients to date.Keywords
Funding Information
- Amgen Inc
This publication has 48 references indexed in Scilit:
- Management of Hyperphosphataemia in Chronic Kidney Disease: Summary of National Institute for Health and Clinical Excellence (NICE) GuidelineNephron Clinical Practice, 2013
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisThe New England Journal of Medicine, 2012
- An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjectsPediatric Nephrology, 2012
- Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT studyNephrology Dialysis Transplantation, 2012
- Early Skeletal and Biochemical Alterations in Pediatric Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2012
- Epidemiology of chronic kidney disease in childrenPediatric Nephrology, 2011
- Volumetric bone mineral density and bone structure in childhood chronic kidney diseaseJournal of Bone and Mineral Research, 2011
- Bone mineral accrual from 8 to 30 years of age: An estimation of peak bone massJournal of Bone and Mineral Research, 2011
- Middle-term use of Cinacalcet in paediatric dialysis patientsPediatric Nephrology, 2010
- Secondary Hyperparathyroidism in Children with Chronic Renal FailurePediatric Drugs, 2003